May 11, 2020 / 12:19 PM / a month ago

BRIEF-Paratek Pharmaceuticals Reports Q1 2020 Total Revenues Of $7.9 Million

May 11 (Reuters) - Paratek Pharmaceuticals Inc:

* PARATEK PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2020 TOTAL REVENUES OF $7.9 MILLION INCLUDING NUZYRA® (OMADACYCLINE) NET SALES OF $7.3 MILLION

* Q1 LOSS PER SHARE $0.66

* Q1 EARNINGS PER SHARE ESTIMATE $-0.80 — REFINITIV IBES DATA

* SEES FY 2020 REVENUE $75 MILLION TO $80 MILLION

* AS OF MARCH 31, 2020, PARATEK HAD $194.8 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES

* CURRENTLY MAINTAINING ITS FULL YEAR 2020 FINANCIAL GUIDANCE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below